Table 4:

Summary of chemotherapeutic agents and their Phase I studies of their use in PIPAC for CRC patients with PM.

	Oxaliplatin	Mitomycin C	Irinotecana
IV dose, mg/m2	85	10	120–185
HIPEC dose, mg/m2	200–460	10-35 [30]	200
PIPAC dose, mg/m2	120 [11]	1.5–7 [32, 34]	20 [32, 33]
	90 [17]
	135 [12]
	92b
Dose-escalation Phase I Study	Yes	No	No
RP2D	90–135 mg/m2	n/a	n/a
Efficacy	16.4% partial response	n/a	n/a
	20.3% stable response (RECIST)
Grade ≥ 3 Toxicity	Pancreatitis, neutropenia, allergic reaction, pain, nausea, peripheral neuropathy	n/a	n/a

^aIn 2018 international survey, only one center used Irinotecan PIPAC [33]. ^barbitrary dose. RP2D, recommended Phase II dose; IV, intravenous; HIPEC, hyperthermic intraperitoneal chemotherapy; PIPAC, pressurized intraperitoneal aerosolized chemotherapy; RECIST 1.1, Response Evaluation Criteria in Solid Tumors.